Real-world safety of switching from originator to biosimilar natalizumab

被引：0
|
作者：
Brustad, Age Winje [1 ]
Hogestol, Einar [2 ,3 ,4 ]
Meling, Martine [2 ]
Celius, Elisabeth Gulowsen [2 ,4 ]
Berg-Hansen, Pal [2 ]
Konig, Marton [2 ,4 ]
Holterbakken, Trine Alm [2 ]
Warren, David [1 ]
Gehin, Johanna [1 ]
Bolstad, Nils [1 ]
Nygaard, Gro Owren [2 ,4 ]
机构：
[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
[2] Oslo Univ Hosp, Dept Neurol, Oslo, Norway
[3] Oslo Univ Hosp, Dept Psychol, Oslo, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1670/563
引用
收藏
页码：1056 / 1057
页数：2
相关论文
共 50 条
  • [21] Safety and effectiveness of follitropin alfa biosimilar to originator follitropin alfa in real-world clinical practice: A Multinational Comparative, Prospective Cohort Study
    Kaplan, S.
    Levy-Toledano, R.
    Davies, M.
    Roy, D.
    Howles, C.
    Lass, A.
    HUMAN REPRODUCTION, 2021, 36 : 406 - 407
  • [22] Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts
    Moura, C. S.
    Lukusa, L.
    Wong, E. C.
    Lakatos, P. L.
    Afif, W.
    Narula, N.
    Bernatsky, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I293 - I293
  • [23] Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies
    Yifei, L.
    Skup, M.
    Yang, M.
    Qi, C.
    Doctor, T.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S334 - S334
  • [24] Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
    Ashish Sharma
    M. Hafeez Faridi
    Nilesh Kumar
    Nikulaa Parachuri
    Rohini Sharma
    Baruch D. Kuppermann
    Francesco Bandello
    Anat Loewenstein
    Carl D. Regillo
    Eye, 2020, 34 : 1008 - 1009
  • [25] Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
    Sharma, Ashish
    Hafeez Faridi, M.
    Kumar, Nilesh
    Parachuri, Nikulaa
    Sharma, Rohini
    Kuppermann, Baruch D.
    Bandello, Francesco
    Loewenstein, Anat
    Regillo, Carl D.
    EYE, 2020, 34 (06) : 1008 - 1009
  • [26] SWITCHING TO BIOSIMILAR INFLIXIMAB: REAL-WORLD DATA FROM THE SOUTHAMPTON BIOLOGIC THERAPIES REVIEW SERVICE
    Holroyd, Christopher
    Parker, Lucy
    Bennett, Sarah
    Zarroug, Jalaa
    Underhill, Caron
    Davidson, Brian
    Armstrong, Ray
    Harvey, Nick
    Dennison, Elaine
    Cooper, Cyrus
    Edwards, Christopher J.
    RHEUMATOLOGY, 2016, 55 : 60 - 61
  • [27] Safety and effectiveness of natalizumab in a real-world multiple sclerosis Portuguese population
    Sequeira, M.
    Ferro, M.
    Barros, A.
    Sousa, A.
    Sequeira, J.
    Parra, J.
    Brum, M.
    Pedrosa, R.
    Capela, C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 868 - 869
  • [28] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [29] OUTCOMES OF BIOSIMILAR ADALIMUMAB SWITCHBACKS/REVERSE SWITCHING IN IBD: REAL-WORLD EXPERIENCE
    Norredinvand, Hesam Ahmadi
    Bishop, Sophia
    Patel, Janki
    Sivanesan, Naveenaa
    Fong, Steven
    GUT, 2021, 70 : A94 - A94
  • [30] Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: A retrospective 12 months follow-up study
    Sakane, Hideo
    Yonemoto, Yukio
    Okamura, Koichi
    Suto, Takahito
    Inoue, Makoto
    Mitomi, Hirofumi
    Tsuchida, Kosei
    Kaneko, Tetsuya
    Tamura, Yasuyuki
    Chikuda, Hirotaka
    JOURNAL OF ORTHOPAEDIC SURGERY, 2024, 32 (02)
12345